Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer

Journal of Proteome Research

Volumn 7, Issue 4, 2008, Pages 1490-1499

  Anderson, Karen S ^a   Ramachandran, Niroshan ^a   Wong, Jessica ^a   Raphael, Jacob V ^a   Hainsworth, Eugenie ^a,c   Demirkan, Gokhan ^a   Cramer, Daniel ^a   Aronzon, Dina ^a   Hodi, F Stephen ^a   Harris, Lyndsay ^b   Logvinenko, Tanya ^d   Labaer, Joshua ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c YALE UNIVERSITY   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Autoantibodies; Biomarker; Breast cancer; Proteomics; Tumor antigen

Indexed keywords

ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER; PROTEIN P53; SURVIVIN; TUMOR ANTIGEN; BIRC5 PROTEIN, HUMAN; EBV ENCODED NUCLEAR ANTIGEN 1; EBV-ENCODED NUCLEAR ANTIGEN 1; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPH NODE; MAJOR CLINICAL STUDY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN STRUCTURE; PROTEOMICS; SEROLOGY; SERUM; TUMOR VOLUME; BLOOD; BREAST TUMOR; FEMALE; IMMUNOLOGY; METHODOLOGY; OVARY TUMOR;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; BIOLOGICAL MARKERS; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, B-LYMPHOCYTE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 45549095664     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr700804c     Document Type: Article

References (72)

1. Early Breast Cancer Tralists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365, (9472), 1687-717.
2. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; Hayes, D. F.; Bast, R. C. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25 (33), 5287-312.
3. Shipitsin, M.; Campbell, L. L.; Argani, P.; Weremowicz, S.; Bloush- tain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Ber-
4. oukhim, R.; Hu, M.; Halushka, M. K.; Sukumar, S.; Parker, L. M.; Anderson, K. S.; Harris, L. N.; Garber, J. E.; Richardson, A. L.; Schnitt, S. J.; Nikolsky, Y.; Gelman, R. S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11 (3), 259-73.
5. Coronella-Wood, J. A.; Hersh, E. M. Naturally occurring B-cell responses to breast cancer. Cancer Immunol. Immunother. 2003, 52 (12), 715-38.
6. Chapman, C; Murray, A.; Chakrabarti, J.; Thorpe, A.; Woolston, C; Sahin, U.; Barnes, A.; Robertson, J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann. Oncol. 2007, 18 (5), 868-73.
7. Soussi, T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000, 60 (7), 1777-88.
8. Disis, M. L.; Pupa, S. M.; Gralow, J. R.; Dittadi, R.; Menard, S.; Cheever, M. A. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 1997, 15 (11), 3363-7.
9. von Mensdorff-Pouilly, S.; Petrakou, E.; Kenemans, P.; van Uffelen, K.; Verstraeten, A. A.; Snijdewint, F. G.; van Kamp, G. J.; Schol, D. J.; Reis, C. A.; Price, M. R.; Livingston, P. O.; Hilgers, J. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 2000, 86 (5), 702-12.
10. Koziol, J. A.; Zhang, J. Y.; Casiano, C. A.; Peng, X. X.; Shi, F. D.; Feng, A. C; Chan, E. K.; Tan, E. M. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 2003, 9 (14), 5120-6.
11. Nesterova, M. V.; Johnson, N.; Cheadle, C; Bates, S. E.; Mani, S.; Stratakis, C. A.; Khan, I. U.; Gupta, R. K.; Cho-Chung, Y. S. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res. 2006, 66 (18), 8971-4.
12. Scanlan, M. J.; Gout, L; Gordon, C. M.; Williamson, B.; Stockert, E.; Gure, A. O.; Jager, D.; Chen, Y. T.; Mackay, A.; O'Hare, M. J.; Old, L. J. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 2001, 1, 4.
13. Chen, Y. T.; Scanlan, M. J.; Sahin, U.; Tureci, O.; Gure, A. O.; Tsang, S.; Williamson, B.; Stockert, E.; Pfreundschuh, M.; Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (5), 1914-8.
14. Schmetzer, O.; Moldenhauer, G.; Riesenberg, R.; Pires, J. R.; Schlag, P.; Pezzutto, A. Quality of recombinant protein determines the amount of autoreactivity detected against the tumor-associated epithelial cell adhesion molecule antigen: low frequency of antibodies against the natural protein. J. Immunol. 2005, 174 (2), 942-52.
15. Pepe, M. S.; Etzioni, R.; Feng, Z.; Potter, J. D.; Thompson, M. L.; Thornquist, M.; Winget, M.; Yasui, Y. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 2001, 93 (14), 1054-61.
16. Crawford, L. V.; Pim, D. C; Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 1982, 30 (4), 403-8.
17. Winter, S. F.; Minna, J. D.; Johnson, B. E.; Takahashi, T.; Gazdar, A. F.; Carbone, D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992, 52 (15), 4168-74.
18. Dowell, S. P.; Wilson, P. O.; Derias, N. W.; Lane, D. P.; Hall, P. A. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. Cancer Res. 1994, 54 (11), 2914- 8.
19. Casey, G.; Lopez, M. E.; Ramos, J. C; Plummer, S. J.; Arboleda, M. J.; Shaughnessy, M.; Karlan, B.; Slamon, D. J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996, 13 (9), 1971-81.
20. Trivers, G. E.; De Benedetti, V. M.; Cawley, H. L.; Caron, G.; Harrington, A. M.; Bennett, W. P.; Jett, J. R.; Colby, T. V.; Tazelaar, H.; Pairolero, P.; Miller, R. D.; Harris, C. C. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin. Cancer Res. 1996, 2(10), 1767-75.
21. Regele, S.; Vogl, F. D.; Kohler, T.; Kreienberg, R.; Runnebaum, I. B. p53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Res. 2003, 23 (IB), 761-4.
22. Jager, D.; Unkelbach, M.; Frei, C; Bert, F.; Scanlan, M. J.; Jager, E.; Old, L. J.; Chen, Y. T.; Knuth, A. Identification of tumor- restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun. 2002, 2, 5.
23. Jager, D.; Taverna, C; Zippelius, A.; Knuth, A. Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunol. Immunother. 2004, 53 (3), 144-7.
24. Wang, X.; Yu, J.; Sreekumar, A.; Varambally, S.; Shen, R.; Giacherio, D.; Mehra, R.; Montie, J. E.; Pienta, K. J.; Sanda, M. G.; Kantoff, P. W.; Rubin, M. A.; Wei, J. T.; Ghosh, D.; Chinnaiyan, A. M. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353 (12), 1224-35.
25. Chatterjee, M.; Mohapatra, S.; Ionan, A.; Bawa, G.; Ali-Fehmi, R.; Wang, X.; Nowak, J.; Ye, B.; Nahhas, F. A.; Lu, K.; Witkin, S. S.; Fishman, D.; Munkarah, A.; Morris, R.; Levin, N. K.; Shirley, N. N.; Tromp, G.; Abrams, J.; Draghici, S.; Tainsky, M. A. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006, 66 (2), 1181-90.
26. Sioud, M.; Hansen, M. H. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur. J. Immunol. 2001, 31 (3), 716-25.
27. Fernandez-Madrid, F.; Tang, N.; Alansari, H.; Granda, J. L.; Tait, L.; Amirikia, K. C.; Moroianu, M.; Wang, X.; Karvonen, R. L. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res. 2004, 64 (15), 5089-96.
28. Qiu, J.; Madoz-Gurpide, J.; Misek, D. E.; Kuick, R.; Brenner, D. E.; Michailidis, G.; Haab, B. B.; Omenn, G. S.; Hanash, S. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumor antigens. J. Proteome Res. 2004, 3(2), 261-7.
29. Zhang, J. Y; Casiano, C. A.; Peng, X. X.; Koziol, J. A.; Chan, E. K.; Tan, E. M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 2003, 12 (2), 136-43.
30. Bouwman, K.; Qiu, J.; Zhou, H.; Schotanus, M.; Mangold, L. A.; Vogt, R.; Erlandson, E.; Trenkle, J.; Partin, A. W.; Misek, D.; Omenn, G. S.; Haab, B. B.; Hanash, S. Microarrays of tumor cell derived proteins uncover a distinct pattern of prostate cancer serum immunoreactivity. Proteomics 2003, 3 (11), 2200-7.
31. Brichory, F. M.; Misek, D. E.; Yim, A. M.; Krause, M. C; Giordano, T. J.; Beer, D. G.; Hanash, S. M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (17), 9824-9.
32. Robinson, W. H.; Steinman, L.; Utz, P. J. Protein arrays for autoantibody profiling and fine-specificity mapping. Proteomics 2003, 3 (11), 2077-84.
33. Hudson, M. E.; Pozdnyakova, I.; Haines, K.; Mor, G.; Snyder, M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc. Natl. Acad. Sci. U.S.A. 2007, 104 (44), 17494-9.
34. Chen, S.; LaRoche, T.; Hamelinck, D.; Bergsma, D.; Brenner, D.; Simeone, D.; Brand, R. E.; Haab, B. B. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat. Methods 2007, 4 (5), 437-44.
35. Ramachandran, N.; Hainsworth, E.; Bhullar, B.; Eisenstein, S.; Rosen, B.; Lau, A. Y.; Walter, J. C; LaBaer, J. Self-assembling protein microarrays. Science 2004, 305 (5680), 86-90.
36. Hollstein, M.; Sidransky, D.; Vogelstein, B.; Harris, C. C. p53 mutations in human cancers. Science 1991, 253 (5015), 49-53.
37. Schlichtholz, B.; Legros, Y; Gillet, D.; Gaillard, C; Marty, M.; Lane, D.; Calvo, F.; Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992, 52 (22), 6380-4.
38. Saleh, J.; Brunner, C; Golzer, R.; Nastainczyk, W.; Montenarh, M. p53 autoantibodies from patients with head and neck cancer recognise common epitopes on the polypeptide chain of p53. Cancer Lett. 2006, 233 (1), 48-56.
39. Volkmann, M.; Sinn, H. P.; Gaugel, D.; Frey, M.; Hajjar, Y.; Ludwig, J.; Hansel, S.; Bastert, G.; Wallwiener, D.; Fiehn, W.; Zentgraf, H.; Huober, J. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 2002, 63 (3), 297-305.
40. Vennegoor, C. J.; Nijman, H. W.; Drijfhout, J. W.; Vernie, L.; Verstraeten, R. A.; von Mensdorff-Pouilly, S.; Hilgers, J.; Verheijen, R. H.; Kast, W. M.; Melief, C. J.; Kenemans, P. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett. 1997, 116 (1), 93-101.
41. Laver, W. G.; Air, G. M.; Webster, R. G.; Smith-Gill, S. J. Epitopes on protein antigens: misconceptions and realities. Cell 1990, 61 (4), 553-6.
42. Tan, E. M.; Shi, F. D. Relative paradigms between autoantibodies in lupus and autoantibodies in cancer. Clin. Exp. Immunol. 2003, 134 (2), 169-77.
43. Lubin, R.; Schlichtholz, B.; Bengoufa, D.; Zalcman, G.; Tredaniel, J.; Hirsch, A.; de Fromentel, C. C.; Preudhomme, C.; Fenaux, P.; Fournier, G.; Mangin, P.; Laurent-Puig, P.; Pelletier, G.; Schlum- berger, M.; Desgrandchamps, F.; Le Due, A.; Peyrat, J. P.; Janin, N.; Bressac, B.; Soussi, T.; et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993, 53 (24), 5872-6.
44. Sangrajrang, S.; Arpornwirat, W.; Cheirsilpa, A.; Thisuphakorn, P.; Kalalak, A.; Sornprom, A.; Soussi, T. Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect. Prev. 2003, 27 (3), 182-6.
45. Goodell, V.; Salazar, L. G.; Urban, N.; Drescher, C. W.; Gray, H.; Swensen, R. E.; Mcintosh, M. W.; Disis, M. L. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J. Clin. Oncol. 2006, 24 (5), 762-8.
46. Regele, S.; Kohlberger, P.; Vogl, F. D.; Bohm, W.; Kreienberg, R.; Runnebaum, I. B. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast. Br. J. Cancer 1999, 81 (4), 702-4.
47. Gao, R. J.; Bao, H. Z.; Yang, Q.; Cong, Q.; Song, J. N.; Wang, L. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters. Breast Cancer Res. Treat. 2005, 93 (2), 111-5.
48. Metcalfe, S.; Wheeler, T. K.; Picken, S.; Negus, S.; Jo Milner, A. P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res. 2000, 2 (6), 438-43.
49. Lenner, P.; Wiklund, F.; Emdin, S. O.; Arnerlov, C; Eklund, C; Hallmans, G.; Zentgraf, H.; Dillner, J. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br. J. Cancer 1999, 79 (5- 6), 927-32.
50. Willsher, P. C; Pinder, S. E.; Robertson, L.; Nicholson, R. I.; Ellis, I. O.; BeU, J. A.; Blarney, R. W.; Green, J. A.; Robertson, J. F. The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res. 1996, 16 (2), 927-30.
51. Zalcman, G.; Schlichtholz, B.; Tredaniel, J.; Urban, T.; Lubin, R.; Dubois, I.; Milleron, B.; Hirsch, A.; Soussi, T. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin. Cancer Res. 1998, 4 (6), 1359-66.
52. Mitsudomi, T.; Suzuki, S.; Yatabe, Y.; Nishio, M.; Kuwabara, M.; Gotoh, K.; Hatooka, S.; Shinoda, M.; Suyama, M.; Ogawa, M.; Takahashi, T.; Ariyoshi, Y. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. J. Natl. Cancer Inst. 1998, 90 (20), 1563-8.
53. Perou, C. M.; Sorlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; Pergamenschikov, A.; Williams, C; Zhu, S. X.; Lonning, P. E.; Borresen-Dale, A. L.; Brown, P. O.; Botstein, D. Molecular portraits of human breast tumours. Nature 2000, 406 (6797), 747- 52.
54. Yagihashi, A.; Ohmura, T.; Asanuma, K.; Kobayashi, D.: Tsuji, N.; Torigoe, T.; Sato, N.; Hirata, K.; Watanabe, N. Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin. Chim. Acta 2005, 362 (1-2), 125-30.
55. Stephen, C. W.; Helminen, P.; Lane, D. P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J. Mol. Biol. 1995, 248 (1), 58-78.
56. PlasmID Database Home page, http://plasmid.med.harvard.edu/PLASMID/.
57. Hu, Y.; Hines, L. M.; Weng, H.; Zuo, D.; Rivera, M.; Richardson, A.; LaBaer, J. Analysis of genomic and proteomic data using advanced literature mining. J. Proteome Res. 2003, 2 (4), 405-12.
58. Ascherio, A.; Munger, K. L.; Lennette, E. T.; Spiegelman, D.; Hernan, M. A.; OIek, M. J.; Hankinson, S. E.; Hunter, D. J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001, 286 (24), 3083-8.
59. Schmollinger, J. C; Vonderheide, R. H.; Hoar, K. M.; Maecker, B.; Schultze, J. L.; Hodi, F. S.; Soiffer, R. J.; Jung, K.; Kuroda, M. J.; Letvin, N. L.; Greenfield, E. A.; Mihm, M.; Kutok, J. L.; Dranoff, G. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (6), 3398-403.
60. Chaudhuri, S.; Cariappa, A.; Tang, M.; Bell, D.; Haber, D. A.; Isselbacher, K. J.; Finkelstein, D.; Forcione, D.; Pillai, S. Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRBl'll may represent protective alleles. Proc. Natl. Acad. Sci. U.S.A. 2000, 97(21), 11451-4.
61. Aaltomaa, S.; Lipponen, P.; Eskelinen, M.; Kosma, V. M.; Marin, S.; Alhava, E.; Syrjanen, K. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur. J. Cancer 1992, 28A (4-5), 859-64.
62. Menard, S.; Tomasic, G.; Casalini, P.; Balsari, A.; Pilotti, S.; Cascinelli, N.; Salvadori, B.; Colnaghi, M. I.; Rilke, F. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin. Cancer Res. 1997, 3 (5), 817-9.
63. Koene, H. R.; Kleijer, M.; Algra, J.; Roos, D.; von dem Borne, A. E.; de Haas, M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997, 90 (3), 1109-14.
64. Weng, W. K.; Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol 2003, 21 (21), 3940-7.
65. Anderson, K.; Aronzon, D.; Keshaviah, A.; Keung, E. Z.; Kamma, M.; Winer, E. P.; Burstein, H. J.; Harris, L. N. Role of host immune response genes in the clinical response to trastuzumab-based therapies. Presented at the 29th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, December 2006.
66. Matzinger, P. The danger model: a renewed sense of self. Science 2002, 296 (5566), 301-5.
67. Apetoh, L.; Ghiringhelli, F.; Tesniere, A.; Obeid, M.; Ortiz, C; Criollo, A.; Mignot, G.; Maiuri, M. C.; Ullrich, E.; Saulnier, P.; Yang, FL; Amigorena, S.; Ryffel, B.; Barrat, F. J.; Saftig, P.; Levi, F.; Lidereau, R.; Nogues, C.; Mira, J. P.; Chompret, A.; Joulin, V.; Clavel- Chapelon, F.; Bourhis, J.; Andre, F.; Delaloge, S.; Tursz, T.; Kroemer, G.; Zitvogel, L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13 (9), 1050-9.
68. Plotz, P. H. The autoantibody repertoire: searching for order. Nat. Rev. Immunol. 2003, 3 (1), 73-8.
69. Tarp, M. A.; Sorensen, A. L.; Mandel, U.; Paulsen, H.; Burchell, J.; Taylor-Papadimitriou, J.; Clausen, H. Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 2007, 17 (2), 197-209.
70. Casciola-Rosen, L.; Andrade, F.; Ulanet, D.; Wong, W. B.; Rosen, A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J. Exp. Med. 1999, 190 (6), 815-26.
71. Kaur, J.; Srivastava, A.; Ralhan, R. Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int. J. Cancer 1997, 74 (6), 609-13.
72. Meister, S.; Schubert, U.; Neubert, K.; Herrmann, K.; Burger, R.; Gramatzki, M.; Hahn, S.; Schreiber, S.; Wilhelm, S.; Herrmann, M.; lack, H. M.; Voll, R. E. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67 (4), 1783-92.